Related references
Note: Only part of the references are listed.Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children
Zhongliang Du et al.
MEDICAL SCIENCE MONITOR (2016)
Epilepsy in India I: Epidemiology and public health
Senthil Amudhan et al.
ANNALS OF INDIAN ACADEMY OF NEUROLOGY (2015)
The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients
Sun Yin-xiang et al.
EPILEPSY RESEARCH (2015)
Prevalence of UGT1A6 polymorphisms in children with epilepsy on valproate monotherapy
Puneet Jain et al.
NEUROLOGY INDIA (2015)
ILAE Official Report: A practical clinical definition of epilepsy
Robert S. Fisher et al.
EPILEPSIA (2014)
The Effect of Uridine Diphosphate Glucuronosyltransferase (UGT)1A6 Genetic Polymorphism on Valproic Acid Pharmacokinetics in Indian Patients with Epilepsy: A Pharmacogenetic Approach
Murali Munisamy et al.
MOLECULAR DIAGNOSIS & THERAPY (2013)
Effects of UGT1A6, UGT2B7, and CYP2C9 Genotypes on Plasma Concentrations of Valproic Acid in Chinese Children with Epilepsy
Yingjie Guo et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients
Xiao-Man Chu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid
Dimitrios Chatzistefanidis et al.
PHARMACOGENOMICS (2012)
Association of genetic variants in six candidate genes with valproic acid therapy optimization
Chin-Chuan Hung et al.
PHARMACOGENOMICS (2011)
Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling
Yi Xing et al.
PHARMACOGENOMICS (2009)
Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome
WHM Peters et al.
JOURNAL OF HEPATOLOGY (2003)
Share Paper
